Ionis Pharmaceuticals, Inc
(https://ionispharma.com) 📸 Data Snapshot: May 30, 2026
Semantic Coherence — The Lens
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Semantic Coherence
Homepage promise vs. Sub-page reality.
18
Impact Weight: 20 / 100
90% Reputation
There is minimal drift between the homepage signal and sub-page substance; the promise to ‘unlock the potential of RNA’ is backed by specific news entries regarding bepirovirsen and diranersen on the news and pipeline sub-pages. The H1 promise of changing the course of human health is ambitious but consistently supported by the clinical trial data presented further down the scroll. Minor drift occurs where generic patient advocacy statements are not immediately linked to the specific therapeutic mechanisms discussed in the news feed.
Semantic Coherence is read from the heading hierarchy first: what each page announces in its H1 and headings, then whether the body actually delivers on it. Below is the structure the engine mapped, followed by the clean text to check for drift between promise and reality.
🏗️ Semantic Structure — heading hierarchy & page identity (the promise the page makes)
HOMEPAGE Innovating to Change the Course of Human Health | IONIS (https://ionispharma.com)
Title
Innovating to Change the Course of Human Health | IONIS
Meta
Discover how we are enabling better futures for people living with serious disease through groundbreaking innovations. Learn about our mission here.
H1 Building on Our Impossible Firsts, We Can Change the Course of Human Health
H2 Main navigation
H2 Footer menu
H2 You are now leaving https://www.ionis.com to visit
H3 Our Science and Technology
H3 WHO WE ARE
H3 JOIN OUR TEAM
H3 LATEST NEWS FEED
H3 Sign Up for News Alerts
H4 Rooted in a Deep Understanding of Genetics
H4 Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Innovating to Change the Course of Human Health | IONIS (https://ionispharma.com/about-us/the-ionis-story/)
Title
Innovating to Change the Course of Human Health | IONIS
Meta
Discover how we are enabling better futures for people living with serious disease through groundbreaking innovations. Learn about our mission here.
H1 Building on Our Impossible Firsts, We Can Change the Course of Human Health
H2 Main navigation
H2 Footer menu
H2 You are now leaving https://www.ionis.com to visit
H3 Our Science and Technology
H3 WHO WE ARE
H3 JOIN OUR TEAM
H3 LATEST NEWS FEED
H3 Sign Up for News Alerts
H4 Rooted in a Deep Understanding of Genetics
H4 Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER (https://ionispharma.com/science-and-innovation/)
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Innovating to Change the Course of Human Health | IONIS (https://ionispharma.com/science-and-innovation/pipeline/)
Title
Innovating to Change the Course of Human Health | IONIS
Meta
Discover how we are enabling better futures for people living with serious disease through groundbreaking innovations. Learn about our mission here.
H1 Building on Our Impossible Firsts, We Can Change the Course of Human Health
H2 Main navigation
H2 Footer menu
H2 You are now leaving https://www.ionis.com to visit
H3 Our Science and Technology
H3 WHO WE ARE
H3 JOIN OUR TEAM
H3 LATEST NEWS FEED
H3 Sign Up for News Alerts
H4 Rooted in a Deep Understanding of Genetics
H4 Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
📝 The Narrative — clean text per page (homepage promise vs. sub-page reality)
HOMEPAGE (https://ionispharma.com) Innovating to Change the Course of Human Health | IONIS
[IMG: Man wearing round sunglasses and a baseball cap leaning on a wire fence] Rick Living with FCS About Ionis [H1] Building on Our Impossible Firsts, We Can Change the Course of Human Health Ionis is unlocking the rapidly expanding potential of RNA- and DNA-targeted medicines to enable better futures for people living with serious diseases. Read Our Story [IMG: Teen in wheelchair spikes volleyball over the net in adaptive volleyball game] PEOPLE & IMPACT [H1] Our 2025 Corporate Responsibility Report: Building Momentum for Better Futures At Ionis, we are focused on bringing better futures to people living with serious diseases. As pioneers in RNA-targeted medicines, we combine deep scientific understanding with innovation and a sense of urgency to deliver life-changing medicines, guided by a commitment to operating responsibly and sustainably. Hear from CEO Brett Monia [IMG: Woman standing wtih her hands behind her back in a mechanics garage] Yajaira Living with sHTG Patient Voices [H1] Living with an Invisible Illness: Yajaira’s Journey with Severe Hypertriglyceridemia (sHTG) For Yajaira, family is everything. She describes them as deeply caring and as her support system through life’s most difficult moments, especially when her very high triglycerides tested her strength in ways she never expected. Learn More About Yajaira's Experience [H3] Our Science and Technology [H4] Rooted in a Deep Understanding of Genetics The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact. [IMG: Explore our Science] Explore Our Science [H3] WHO WE ARE Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them. [IMG: Pipeline Icon] OUR PIPELINEWe have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs. [IMG: Review Our Pipeline] Review Our Pipeline [IMG: Patients & Advocacy Icon] WORKING TO MAKE EVERY LIFE AS FULL AS POSSIBLEWe push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world. [IMG: Find Out How] Find Out How [IMG: Corporate Responsibility Icon] CORPORATE RESPONSIBILITYWe believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world. [IMG: Learn more about our committment] Learn More About Our Commitment [H3] JOIN OUR TEAM [H4] Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us. [IMG: Apply Today] Apply Today [IMG: Man in Glasses Black & White] [H3] LATEST NEWS FEED [IMG: Read More] [H3] Sign Up for News Alerts [IMG: Sign Up] For the latest on Ionis news and developments 2026-05-28T04:45:00EDTIonis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B– Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – – 49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in https://ir.ionis.com/news-releases/news-release-details/ionis-partner-gsk-annou… 2026-05-14T07:05:00EDTIonis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease- Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - - Robust reductions in tau pathology were observed across all studied doses, with results generally https://ir.ionis.com/news-releases/news-release-details/ionis-partner-biogen-an… 2026-05-04T07:05:00EDTIonis to host 2026 virtual Annual Meeting of StockholdersCARLSBAD, Calif. --(BUSINESS WIRE)--May 4, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. https://ir.ionis.com/news-releases/news-release-details/ionis-host-2026-virtual… Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).
5411 chars
SUB-PAGE (https://ionispharma.com/about-us/the-ionis-story/) Innovating to Change the Course of Human Health | IONIS
[IMG: Man wearing round sunglasses and a baseball cap leaning on a wire fence] Rick Living with FCS About Ionis [H1] Building on Our Impossible Firsts, We Can Change the Course of Human Health Ionis is unlocking the rapidly expanding potential of RNA- and DNA-targeted medicines to enable better futures for people living with serious diseases. Read Our Story [IMG: Teen in wheelchair spikes volleyball over the net in adaptive volleyball game] PEOPLE & IMPACT [H1] Our 2025 Corporate Responsibility Report: Building Momentum for Better Futures At Ionis, we are focused on bringing better futures to people living with serious diseases. As pioneers in RNA-targeted medicines, we combine deep scientific understanding with innovation and a sense of urgency to deliver life-changing medicines, guided by a commitment to operating responsibly and sustainably. Hear from CEO Brett Monia [IMG: Woman standing wtih her hands behind her back in a mechanics garage] Yajaira Living with sHTG Patient Voices [H1] Living with an Invisible Illness: Yajaira’s Journey with Severe Hypertriglyceridemia (sHTG) For Yajaira, family is everything. She describes them as deeply caring and as her support system through life’s most difficult moments, especially when her very high triglycerides tested her strength in ways she never expected. Learn More About Yajaira's Experience [H3] Our Science and Technology [H4] Rooted in a Deep Understanding of Genetics The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact. [IMG: Explore our Science] Explore Our Science [H3] WHO WE ARE Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them. [IMG: Pipeline Icon] OUR PIPELINEWe have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs. [IMG: Review Our Pipeline] Review Our Pipeline [IMG: Patients & Advocacy Icon] WORKING TO MAKE EVERY LIFE AS FULL AS POSSIBLEWe push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world. [IMG: Find Out How] Find Out How [IMG: Corporate Responsibility Icon] CORPORATE RESPONSIBILITYWe believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world. [IMG: Learn more about our committment] Learn More About Our Commitment [H3] JOIN OUR TEAM [H4] Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us. [IMG: Apply Today] Apply Today [IMG: Man in Glasses Black & White] [H3] LATEST NEWS FEED [IMG: Read More] [H3] Sign Up for News Alerts [IMG: Sign Up] For the latest on Ionis news and developments 2026-05-28T04:45:00EDTIonis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B– Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – – 49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in https://ir.ionis.com/news-releases/news-release-details/ionis-partner-gsk-annou… 2026-05-14T07:05:00EDTIonis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease- Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - - Robust reductions in tau pathology were observed across all studied doses, with results generally https://ir.ionis.com/news-releases/news-release-details/ionis-partner-biogen-an… 2026-05-04T07:05:00EDTIonis to host 2026 virtual Annual Meeting of StockholdersCARLSBAD, Calif. --(BUSINESS WIRE)--May 4, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. https://ir.ionis.com/news-releases/news-release-details/ionis-host-2026-virtual… Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).
5411 chars
SUB-PAGE · THIN (https://ionispharma.com/science-and-innovation/)
0 chars
SUB-PAGE (https://ionispharma.com/science-and-innovation/pipeline/) Innovating to Change the Course of Human Health | IONIS
[IMG: Man wearing round sunglasses and a baseball cap leaning on a wire fence] Rick Living with FCS About Ionis [H1] Building on Our Impossible Firsts, We Can Change the Course of Human Health Ionis is unlocking the rapidly expanding potential of RNA- and DNA-targeted medicines to enable better futures for people living with serious diseases. Read Our Story [IMG: Teen in wheelchair spikes volleyball over the net in adaptive volleyball game] PEOPLE & IMPACT [H1] Our 2025 Corporate Responsibility Report: Building Momentum for Better Futures At Ionis, we are focused on bringing better futures to people living with serious diseases. As pioneers in RNA-targeted medicines, we combine deep scientific understanding with innovation and a sense of urgency to deliver life-changing medicines, guided by a commitment to operating responsibly and sustainably. Hear from CEO Brett Monia [IMG: Woman standing wtih her hands behind her back in a mechanics garage] Yajaira Living with sHTG Patient Voices [H1] Living with an Invisible Illness: Yajaira’s Journey with Severe Hypertriglyceridemia (sHTG) For Yajaira, family is everything. She describes them as deeply caring and as her support system through life’s most difficult moments, especially when her very high triglycerides tested her strength in ways she never expected. Learn More About Yajaira's Experience [H3] Our Science and Technology [H4] Rooted in a Deep Understanding of Genetics The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact. [IMG: Explore our Science] Explore Our Science [H3] WHO WE ARE Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them. [IMG: Pipeline Icon] OUR PIPELINEWe have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs. [IMG: Review Our Pipeline] Review Our Pipeline [IMG: Patients & Advocacy Icon] WORKING TO MAKE EVERY LIFE AS FULL AS POSSIBLEWe push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world. [IMG: Find Out How] Find Out How [IMG: Corporate Responsibility Icon] CORPORATE RESPONSIBILITYWe believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world. [IMG: Learn more about our committment] Learn More About Our Commitment [H3] JOIN OUR TEAM [H4] Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us. [IMG: Apply Today] Apply Today [IMG: Man in Glasses Black & White] [H3] LATEST NEWS FEED [IMG: Read More] [H3] Sign Up for News Alerts [IMG: Sign Up] For the latest on Ionis news and developments 2026-05-28T04:45:00EDTIonis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B– Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – – 49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in https://ir.ionis.com/news-releases/news-release-details/ionis-partner-gsk-annou… 2026-05-14T07:05:00EDTIonis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease- Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - - Robust reductions in tau pathology were observed across all studied doses, with results generally https://ir.ionis.com/news-releases/news-release-details/ionis-partner-biogen-an… 2026-05-04T07:05:00EDTIonis to host 2026 virtual Annual Meeting of StockholdersCARLSBAD, Calif. --(BUSINESS WIRE)--May 4, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. https://ir.ionis.com/news-releases/news-release-details/ionis-host-2026-virtual… Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).
5411 chars
Explore the other reputation pillars for Ionis Pharmaceuticals, Inc
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from Ionis Pharmaceuticals, Inc, captured on May 30, 2026, to show how machine logic reads Semantic Coherence signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Ionis Pharmaceuticals, Inc: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://ionispharma.com to view the most current version of its content and see directly what this company is about and what it offers.